SIRT1 and gastric cancer: In gastric cancer (GC), SIRT1 silencing or inhibiting its activity by EX527 enhances expression of FOXO1, pro-apoptotic BAX, and E-cadherin, whereas the expression of Ki67, Cyclin D1, anti-apoptotic Bcl-2, Vimentin, MMP-2 and MMP-9 are downregulated, suggesting SIRT1 involvement in GC progression (Figure 3E) [82].